lipid-banner
lipid-banner-mobile

Plaque imaging

Imaging techniques used to visualize atherosclerotic plaques1,2

Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) offer complementary information about plaque.

Primary Use of IVUS
Primary Use of OCT
Insight into plaque volumeDetection of specific features of plaque vulnerability

IVUS measures the extent and distribution of atherosclerotic plaque1,2

IVUS produces cross-sectional images of the lumen and coronary artery wall using catheter-based ultrasound transducers, reaching 100 μm resolution. This allows for the assessment of changes in plaque burden.

IVUS provides:1,2
Deeper tissue penetration
Volumetric quantification of atheroma (plaque size) within the entire vessel wall (from intima to adventitia)
An evaluation of changes in plaque burden over time

OCT offers high resolution necessary to detect characteristics of vulnerable plaque, including lipid core and fibrous cap1,2

OCT PROVIDES:

Cross sectional images icon

Cross-sectional images

Depicts the lumen and superficial layer (intimal) of the arterial wall by measuring near-infrared light intensity reflected from tissue

plaque vulnerability icon

The highest spatial resolution capability
(< 10μm)

Allows for higher sensitivity to detect certain features of plaque vulnerability, including the fibrous cap and the lipid core

Comparison of OCT and IVUS imaging modalities to assess plaque characteristics1

Imaging
modality
Resolution Penetration Fibrous cap Lipid core Inflammation Calcium Thrombus Assesses Plaque Burden Current
Status
IVUS 100µm Good + ++ +++ + Yes2,3,* CS/CA
OCT 10µm Poor +++ +++ + +++ + Limited2,3,† CS

+++ = sensitivity > 90%
++ = sensitivity 80% to 90% 
+ = sensitivity 50% to 80%
– = sensitivity < 50%

*Assesses plaque burden and identifies vulnerable plaque characteristics.

Identifies certain characteristics of vulnerable plaque, including fibrous cap and lipid core, but poor depth of penetration to assess deep plaque structures and plaque volume.

CS = clinical studies; CA = clinically approved for commercial use.

  • References

    1. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: current status. Arterioscler Thromb Vasc Biol. 2003;23:1333-1342.
    2. Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging. 2011;4:319-333.